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Background/aim: To investigate the distribution of viral genotypes, the extrahepatic manifestations, and the relationship between
genotypes and extrahepatic manifestations in patients with chronic hepatitis C.
Materials and methods: The study included 62 treatment-naive patients with chronic hepatitis C infection. Genotype determination
was performed by DNA sequencing analysis. To investigate extrahepatic manifestations, the patients’ data, recorded prospectively
during the pretreatment period, were analyzed.
Results: Genotype determination was successful in 74.2% of the cases. All patients were infected with hepatitis C virus (HCV) genotype
1b. At least 1 extrahepatic manifestation was identified in 37.1% of the patients. The most frequent clinical manifestations were type II
diabetes mellitus (8.1%) and arthralgia or arthritis (8.0%). There was no relationship between extrahepatic manifestations and fibrosis
or transaminase levels, but female sex and advanced age were risk factors. Because all patients were infected with the same genotype, the
relationship between extrahepatic manifestations and genotype could not be examined.
Conclusion: HCV genotype 1b is predominant in patients with chronic hepatitis C in the Eastern Anatolian Region of Turkey. In total,
37.1% of the patients had at least 1 extrahepatic manifestation. Female sex and advanced age were risk factors for having extrahepatic
manifestations.
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1. Introduction
The hepatitis C virus (HCV) is one of the major causes of
liver cirrhosis, liver cancer, and chronic illnesses all over
the world. According to a report of the World Health
Organization, more than 280,000 deaths from chronic liver
illness in 2001 were linked to HCV infection (1). HCV is
in the family Flaviviridae and the genus Hepaciviridae.
HCV isolates are classified as genotypes and subtypes. Six
genotypes and more than 80 subtypes have been identified.
These differ in nucleotide sequence by more than 30%
over the complete virus genome. A number of subtypes,
which differ in nucleotide sequence by more than 20%,
have also been described (2). The genotypes of HCV show
a distinct geographical distribution. Genotype 1b, which
accounts for 40%–80% of isolates all over the world, is the
most widespread genotype. Genotypes 1a, 1b, and 2a are
the predominant genotypes in the United States and West
Europe. Genotype 4 is the predominant genotype in the
* Correspondence: sererol@gmail.com
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Middle East. Types 5 and 6 are largely confined to South
Africa and South East Asia (2). In Turkey, the predominant
genotype is 1b (66.7%–100%) (3–5).
Genotypes are important epidemiological markers
of HCV and predictors of therapeutic response. Patients
infected with genotype 1b are less likely to have a sustained
virological response than those infected with genotypes 2
and 3. It is known that the sensitivity of first- and secondgeneration enzyme-linked immunosorbent assay (ELISA)
tests is influenced by the infecting genotypes. However, the
role of HCV genotypes in clinical features, severity, and
progression of liver disease and extrahepatic manifestations
is controversial. Possible links to more severe liver disease
and hepatocellular carcinoma have been reported for HCV
genotype 1b. HCV-related cirrhosis and hepatocellular
carcinoma can occur over a short period in some patients,
whereas others have no complications despite a longer
period of infection. In addition, it is known that genotype
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1b causes an earlier reappearance of more serious hepatitis
in liver transplant recipients (2,6,7).
Some extrahepatic disorders including essential mixed
cryoglobulinemia (EMC), lichen planus, type II diabetes
mellitus (DM), thyroid dysfunctions, thrombocytopenia,
porphyria cutanea tarda, local lymphocytic sialadenitis,
Mooren ulcers, vasculitic neuropathy, glomerulonephritis,
and polyarteritis nodosa can be accompanied by
chronic HCV infection. Idiopathic pulmonary fibrosis,
pancreatitis, pericarditis, and amyloidosis can also be
associated. Up to 30%–70% of the patients might develop
at least 1 extrahepatic manifestation during the course
of the disease. As a consequence of chronic infection,
an accumulation of circulating immune complexes may
be the cause of the extrahepatic disorders. However, the
exact mechanism is not known (8,9). The literature on
the relation between HCV genotypes and extrahepatic
manifestations is controversial and ambiguous (10–13).
The aims of this study were to investigate the distribution
of HCV genotypes and extrahepatic manifestations, and
to identify the relationship between the genotypes and
extrahepatic manifestations among patients with chronic
hepatitis C in the Eastern Anatolian Region of Turkey
2. Materials and methods
The study included treatment-naive patients with chronic
hepatitis C infection admitted to the Department of
Infectious Diseases and Clinical Microbiology of Atatürk
University Medical School during the period from
November 2008 to April 2010. Chronic HCV infection
was considered on the basis of positive serum anti-HCV
antibodies by third-generation ELISA assay (Dia.Pro
Diagnostic, Italy), and positive serum HCV-RNA by a
real-time polymerase chain reaction (PCR) assay (Artus
HCV RG RT-RCR Kit, Germany) for at least 6 months
and/or liver biopsy consistent with chronic hepatitis.
HCV genotyping was performed by pyrosequencing
technology, a real-time sequence analysis method based
on the detection of pyrophosphate that is released during
the synthesis of nucleic acid, on a PyroMark Q24 sequence
analyzer (Germany) as described by the protocol of the
manufacturer.
The patients’ demographic features and disease histories
were recorded. All patients were subjected to physical
examinations for their general status and symptoms
related to extrahepatic manifestations. Complete urine
tests; blood tests including fasting blood glucose, alanine
aminotransferase (ALT), aspartate aminotransferase
(AST), prothrombin time (PT), partial thromboplastin
time (PTT), alpha-fetoprotein, and thyroid hormone
levels; and an abdominal ultrasonography were performed
on all patients. HBsAg, HBeAg, anti-HBs, anti-HBe, antiHBc total, and anti-HIV antibodies were also measured

by the ELISA method (Dia.Pro Diagnostic). The patients
with hepatitis B virus–HCV coinfections were excluded
from the study. Patients were assigned a diagnosis of DM if
they were using oral hypoglycemic medication or insulin,
or if they had random glucose greater than 200 mg/dL,
fasting glucose greater than 126 mg/dL, or glycosylated
hemoglobin A1c (HbA1c) above than 6.5% on 2 occasions.
Peripheral blood smear and respiratory functions tests
were performed if deemed necessary. A liver biopsy was
performed in 30 patients diagnosed with chronic HCV
infection who gave their informed consent beforehand.
A biopsy was not performed if the patient refused the
procedure.
Serum antinuclear antibody (ANA), antismall
muscle antibody (ASMA), antiliver kidney microsomal
antibody-1 (LKM-1), antimitochondrial antibody
(AMA), and antithyroid antibodies were investigated by
an immunofluorescence method (Euroimmun, Lübeck,
Germany).
Cryoglobulins were determined qualitatively. Ten
milliliters of whole blood was incubated in a Benmari
incubator at 37 °C for 30 min and then centrifuged at 3000
rpm for 10 min. A 5-mL serum sample was kept at 4 °C for
3 days. The sera were checked every 30 min on the first day
and once a day thereafter. The presence of a cryoprecipitate
was considered positive.
2.1. Statistical analysis
Statistical analysis was performed with SPSS 18.0 (SPSS
Inc., USA). Quantitative data were expressed as mean ±
SD and Student’s t-test was employed for comparison.
For nonparametric variables Mann–Whitney tests and
Wilcoxon’s signed ranks tests were used, and P ≤ 0.05 was
considered significant.
3. Results
This study included 62 patients with chronic hepatitis
C, 32 (51.6%) males and 30 (48.4%) females. The mean
age was 49.74 ± 11.61 years. Viral genotype could be
determined in 46 patients (74.2%). Genotype 1b was
the sole genotype. A total of 23 patients had 1 or more
extrahepatic manifestations. Of the patients who had
extrahepatic manifestation, 15 (65.2%) were female and 8
(34.8%) were male (P < 0.05). The characteristics of the
patients are shown in Table 1.
Type II DM was the most common extrahepatic
manifestation. No patient had cryoglobulinemia. The
distributions of extrahepatic manifestations are shown in
Table 2.
Because all patients were infected with genotype 1b,
the relation of extrahepatic manifestations to genotypes
was not ascertained. Extrahepatic manifestations were
more common at advanced ages and in female patients.
Although the mean ALT values were not different, the
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Table 1. Characteristics of patients (mean ± standard deviation).

Age, years

Patients with extrahepatic
manifestations (n = 23)

Patients without extrahepatic
P
manifestations (n = 39)

53.0 ± 8.2

43.86 ± 14.8

Sex, female, n

15 (65.2%)

15(38.5%)

<0.05

ALT (U/L)

5.09 ± 37.7

52.68 ± 38.0

>0.5

HCV-RNA (copies/mL)

13,055 × 106 ± 26,355 × 106

19,042 × 108 ± 851,293 × 108

<0.05

Biopsy, n Fibrosis
FO
FI
F3

15
6.7%
53.3%
40%

15
20%
40%
40%

<0.05
<0.05
>0.05

mean HCV-RNA value was greater in patients having
extrahepatic manifestations than in those not having
extrahepatic manifestations. There was no case of
hepatocellular carcinoma or cirrhosis in our patient
population, but 60% of them had moderate liver fibrosis.
Liver fibrosis scores were also different among patients
with and without extrahepatic manifestations (Table 1).
4. Discussion
In this study, genotype determination could be done in
46 of the 62 patients, and all were genotype 1b. Various
studies report a failure to determine HCV genotype in 0%–
44% of patients (14–17). Genotype determination rates
vary by sample handling procedure and analysis method.
According to the results of many other studies, genotype
1b is the most prevalent (66%–100%) HCV genotype in
Turkey, and our findings are compatible with these results
Table 2. The distributions of extrahepatic manifestations.
Extrahepatic manifestations

Females,
n (%)

Males,
n (%)

Total,
n (%)

Type II DM*

3 (10)

2 (6.2)

5 (8)

Depression

2 (6.6)

1 (3.1)

3 (4.8)

Arthralgia

2 (6.6)

1 (3.1)

3 (4.8)

Pruritus

2 (6.6)

1 (3.1)

3 (4.8)

Asthma

1 (3.3)

1 (3.1)

2 (6.2)

COPD**

1 (3.3)

1 (3.1)

2 (6.2)

Arthritis

2 (6.6)

0 (0)

2 (6.2)

ANA positivity

1 (3.3)

0 (0)

1 (3.2)

Anti-LKM-1 positivity

0 (0)

1 (3.1)

1 (3.2)

Hypothyroidism

1 (3.3)

0 (0)

1 (3.2)

Cryoglobulinemia

0

0

0

Total

15 (24.2)

8 (12.9)

23 (37.1)

*: Diabetes mellitus, **: chronic obstructive pulmonary disease.
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<0.05

(3–5,14–20). In a comprehensive survey, 87.2% of the
patients had genotype 1b, 9.9% had genotype 1a, 0.9% had
genotype 2, 1.4% had genotype 3, and 0.6% had genotype
4 (18). In another study from İstanbul, genotypes 1b, 3a,
4e, 2a/2c, 1a, and 4 were found in 76.9%, 9.6%, 5.7%, 3.8%,
1.9%, and 1.9% of the patients, respectively (19). Genotypes
2 and 3 were more common in younger patients.
Today, the clinical significance of HCV genotypes is
still debatable. However, it is accepted that HCV genotype
determination is important in predicting treatment
response and defining the duration of the treatment and
the dosage of antiviral drugs (6,7,21). The relationship
of the genotypes with clinical features, extrahepatic
manifestations, and prognosis is controversial. Some
studies have shown an association between liver illness,
hepatocellular carcinoma, and cirrhosis and genotype
1b (2,7). In a study from Turkey there was no relation
between HCV genotypes and age, sex, transmission
history, ALT level, or liver histopathology (3). It is
suggested that genotypes 1b and 2 appear in older age
groups in comparison with 1a, 3, and 4 and that HCV
genotype has no relation with the levels of AST and ALT
(2,19,22). Because all of our patients were infected with
genotype 1b, we could not investigate any relationship for
these parameters. Since multiple hosts and viral factors
can contribute to variations in the natural history of
diseases, it is hard to see the role of the viral genotype as
an independent factor. In this study, there was no relation
between extrahepatic manifestations and liver fibrosis
score. Moreover, HCV-RNA levels were lower among the
patients who had extrahepatic manifestations than those
who did not (Table 1).
According to different studies, 40%–74% of patients
infected with HCV might develop at least 1 extrahepatic
manifestation during the course of the disease (13,23–25).
In the present study, the rate was 37.1%, and it increased
with age. Extrahepatic manifestations were more prevalent
among female patients. The limitation of this study is the
lack of a control group. Although some studies revealed
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a female preponderance, there are also other studies that
showed no sexual difference, or a male preponderance
(26–28).
EMC is one of the most prevalent extrahepatic
manifestations in this patient population, with prevalences
of 3%–54% (8,9). The rates are lower (0%–32%) in studies
from Turkey (29–31). Our study also supports these lower
rates. Clinical manifestations in cryoglobulinemic patients
are purpura, skin ulcers, Raynaud’s phenomenon, systemic
vasculitis, glomerulonephritis, and neuropathy. None of
these were detected in our patient population. A prior
study suggested that genotype 2c has a strong relation with
EMC, while genotype 1b seems to prevent its onset (13). In
considering our unique 1b genotype, it is not surprising to
see no cryoglobulinemia in this study.
The association of pruritus with chronic HCV infection
is reported to be 10%–15% in the literature. Pruritus
during HCV infection is accepted as an immunological
phenomenon and is generally seen in patients with more
advanced histological lesions; reports on response to
antiviral treatment are inconsistent (9,26,31–33). Pruritus
was an uncommon manifestation in our cases. In contrast
to some previous reports, pruritus resolved spontaneously
after antiviral treatment in the patients who had treatment
response.
Functional thyroid disorders and autoimmune
thyroiditis can accompany chronic HCV infection or
develop during antiviral treatment (6). As many as 13%
of HCV-infected patients (especially older women)
have hypothyroidism, and up to 25% have thyroid
antibodies independent of the stage of liver disease (9,30).
Hypothyroidism was noted in 1 patient is this study (1.6%).
However, we could not detect thyroid antibodies.
There are numerous reports about the association
between chronic HCV infection and type II DM, which
is attributed to severe liver damage and fibrosis, or is
independent of the degree of fibrosis (34,35). In this study,
type II DM was the most prevalent extrahepatic disease,
and 4 of 5 patients with DM had severe fibrosis.
Arthralgia and arthritis are other common extrahepatic
manifestations in patients with chronic HCV infection.
The exact mechanism of arthritis has not been determined,
but it is thought to be a local inflammatory response to
synovial tissue damage caused directly by viral invasion or
indirectly by deposition of cryoglobulin. In comparison
with other reports, prevalences of arthralgia and arthritis
were much lower in this study (24,36).
Depressive disorders can be found in 50% of patients
with HCV infection and can potentially be exacerbated by
interferon-alpha treatment (31,37). Depression also has a

negative effect on treatment compliance. Our rate of 4.8%
is lower than those of previous studies.
Several studies suggest that anti-HCV antibody
prevalence is higher among patients with chronic
obstructive pulmonary disease (COPD) than those
without COPD (11,38). In a previous study from Erzurum,
anti-HCV prevalence was 8.3% among these patients
(11). Otherwise, the prevalence of COPD was 17.6%
among patients who had the anti-HCV antibody. In this
study, 6.2% of the patients had a diagnosis of COPD. The
coexistence of COPD and HCV infection was lacking in
other reports (28,39).
As a virus-induced autoimmune phenomenon,
persistent HCV infection triggers production of a number
of organ-specific and nonorgan-specific autoantibodies.
The diversity of autoantibodies in the sera of patients
with HCV-related chronic liver disease has been shown.
In our study, ANA and anti-LKM-1 positivity was 1.6%,
which is much less than in other literature reports. The
titers of these autoantibodies seem to be independent
of HCV genotypes or HCV-RNA load (40). Because of
the limited number of patients with autoantibodies, we
could not perform an investigation of this link. Some
studies indicate a link between HCV infection and nonHodgkin lymphoma, Sjögren’s syndrome, amyloidosis, or
pancreatitis (41,42). These disorders were not encountered
in our study population.
In recent years, the relation between extrahepatic
manifestations and HCV genotypes has been investigated
(12,13). In a prior study, the genotype 2c was related
to EMC, carpal tunnel syndrome, and autoimmune
thyroiditis, whereas, on the contrary, genotype 1b seemed
to prevent EMC (12). The association of extrahepatic
manifestations with the genotypes could not be determined
in another study (13). Due to the fact all our patients were
infected with the same genotype, the relationship between
extrahepatic manifestations and genotype could not be
examined in this study.
In conclusion, as throughout all of Turkey, the
predominant HCV genotype is 1b in the Eastern Anatolian
Region. Chronic HCV infection is accompanied by some
extrahepatic manifestations in 37% of the patients. The
most prevalent extrahepatic manifestation in the study
region is type II DM. An association between EMC and
HCV infection was not determined in this study. Female
sex and advanced age are risk factors for extrahepatic
manifestations. Because genotype 1b was the unique
genotype in this study population, the relationship
between extrahepatic manifestations and genotype could
not be examined.
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